Sonoma Pharmaceuticals (SNOA) Other Non-Current Liabilities (2011 - 2026)

Sonoma Pharmaceuticals' Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $5.6 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 8.21% year-over-year to $5.6 million in Q1 2026; TTM through Mar 2026 was $5.6 million, a 8.21% increase from a year earlier, with the FY2026 full-year figure at $5.6 million, up 8.21% from the prior year.
• Other Non-Current Liabilities rose to $5.6 million in Q1 2026 per SNOA's latest filing, from $5.5 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $5.6 million in Q1 2026 and bottomed at $3.8 million in Q1 2022.
• The 5-year median for Other Non-Current Liabilities is $4.7 million (2024), against an average of $4.7 million.
• Across the five-year window, Other Non-Current Liabilities rose 12.06% in 2023 and grew 8.21% in 2026, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $4.1 million in 2022, then gained by 12.06% to $4.6 million in 2023, then rose by 9.69% to $5.0 million in 2024, then climbed by 8.52% to $5.5 million in 2025, then advanced by 1.81% to $5.6 million in 2026.
• Per Business Quant, the three latest SNOA Other Non-Current Liabilities figures stand at $5.6 million (Q1 2026), $5.5 million (Q4 2025), and $5.4 million (Q3 2025).